Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT03797001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03797001
Other papers using this trial's data
  • Interleukin-1 Receptor Antagonist Levels in Patients With Heart Failure and Reduced Ejection Fraction Treated With Anakinra Journal of cardiovascular pharmacology, 2026-08-01 DOI, PubMed 42455969
  • Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra Circulation. Heart failure, 2026-03 DOI, PubMed 41431894, PMC12747512 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03797001. Randomized; quadruple masking; primary purpose treatment. Start 2019-01-04 (actual); primary completion 2024-07-22 (actual). Results posted on 2025-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
Acronym
REDHART2
Condition
Heart Failure, Systolic
Condition
Inflammation
Intervention (Drug)
Anakinra
Intervention (Drug)
Placebo
Lead sponsor
Virginia Commonwealth University (class: other)

Record details

Record id
cardio:ct-nct03797001
Content hash
bca32309c3efec49476422627caf9c4e1cbaaad48471566a6d2bb481fca59f35